Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
Key facts
- Who runs it
- University of Maryland, Baltimore
- Where
- Baltimore, Glen Burnie, and Towson, United StatesSee the 4 sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 900 people, planned
- Starts
- 1 Feb 2027
- Expected to end
- 30 Sept 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Ceftriaxone 1 gram daily
- Ceftriaxone 2 grams daily
- Record updated
- 5 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (4)Hide the full registry criteria
Who can take part
- Evaluated in the emergency department or within 72 hours of hospitalization
- Prescribed Ceftriaxone for community-acquired pneumonia
Who cannot take part
- Respiratory failure requiring mechanical ventilation, non-invasive ventilation such as bilevel positive airway pressure, or high flow nasal cannula
- Planned or present admission to an intensive care unit
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Community acquired pneumonia
Where in United States
- University of Maryland Medical CenterBaltimore, United StatesContact: Megan Dunning, MDNot yet recruiting
- University of Maryland Medical Center - Midtown CampusBaltimore, United StatesContact: Jonathan Baghdadi, MD, PhDNot yet recruiting
- UM Baltimore Washington Medical CenterGlen Burnie, United StatesContact: Stephanie Pires, PharmDNot yet recruiting
- University of Maryland St. Joseph Medical CenterTowson, United StatesContact: Rose Kohinke, PharmDNot yet recruiting
About the trial
What the trial wants to find out
Aim: Demonstrate the equivalent efficacy and superior safety of Ceftriaxone 1 gram daily compared with Ceftriaxone 2 grams daily among hospitalized patients with community-acquired pneumonia who are not admitted to the intensive care unit.<p>
Read full original descriptionShow less
Hypothesis: Among hospitalized patients outside of the intensive care unit with community-acquired pneumonia who are prescribed Ceftriaxone, a dosage of 1 gram daily will be associated with an equivalent rate of clinical cure and fewer adverse events than a dosage of 2 grams daily.
The 2 groups in the trial
- Low Dose CeftriaxoneExisting treatment, for comparison
Intravenous Ceftriaxone will be dosed 1 gram daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit.
Treatment: Ceftriaxone 1 gram daily
- Moderate Dose CeftriaxoneExisting treatment, for comparison
Intravenous Ceftriaxone will be dosed 2 grams daily per institutional guidance for treatment of community-acquired pneumonia outside of the intensive care unit.
Treatment: Ceftriaxone 2 grams daily
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Pragmatic Randomized Trial Evaluating Dosage of Ceftriaxone for Community-Acquired Pneumonia Outside the Intensive Care Unit
- Criteria questions
- Built from NCT07537413, who can take part
- Record updated
- 5 November 2026